Most cited papers from Bial (Portugal)

Bial (Portugal)

What are the most cited papers from Bial (Portugal)?

The most cited paper from Bial (Portugal) is "Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs" (Teófilo Vasconcelos, Bruno Filipe Carmelino Cardoso Sarmento, Paulo C. Costa, 2007), with 1,565 citations. Next come "Pharmacokinetic and safety profile oftrans‐resveratrol in a rising multiple‐dose study in healthy volunteers" (428) and "Amorphous solid dispersions: Rational selection of a manufacturing process" (381).

Published TypeFieldAccessCitations

Showing 50 of 61 papers. Every paper with more than 61 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Teófilo Vasconcelos, Bruno Filipe Carmelino Cardoso Sarmento, Paulo C. Costa · Drug Discovery Today	Dec 2007	1,565
2	Pharmacokinetic and safety profile oftrans‐resveratrol in a rising multiple‐dose study in healthy volunteers Luís Guilherme Batista Almeida, Manuel Vaz‐da‐Silva, Amílcar C. Falcão et al. · Molecular Nutrition & Food Research	4 Feb 2009	428
3	Amorphous solid dispersions: Rational selection of a manufacturing process Teófilo Vasconcelos, Sara Rejane Oliveira Marques, José das Neves et al. · Advanced Drug Delivery Reviews Review	27 Jan 2016	381
4	Mechanisms of Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024 António Francisco Ambrósio, Patrı́cio Soares-da-Silva, Caetana Monteiro Carvalho et al. · Neurochemical Research	Feb 2002	294
5	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial Joaquim José Ferreira, Andrew John Lees, José‐Francisco Rocha et al. · The Lancet Neurology	22 Dec 2015	291
6	Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study Christian Erich Elger, Péter Halász, Joana Maia et al. · Epilepsia	23 Feb 2009	252
7	Catechol‐ O ‐methyltransferase and Its Inhibitors in Parkinson's Disease Maria João Bonifácio, P. Nuno Palma, Luís Guilherme Batista Almeida et al. · CNS Drug Reviews Open access	Sep 2007	199
8	Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine-5-carboxamide Derivatives Jan Beneš, António Parada, Anabela A. Figueiredo et al. · Journal of Medicinal Chemistry Open access	17 Jun 1999	197
9	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations Andrew John Lees, Joaquim José Ferreira, Olivier Rascol et al. · JAMA Neurology	27 Dec 2016	189
10	Eslicarbazepine Acetate (BIA 2-093) Luís Guilherme Batista Almeida, Patrı́cio Soares-da-Silva · Neurotherapeutics Open access	2007	186
11	Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy Elinor Ben‐Menachem, Alberto Alain Gabbai, A. Hufnagel et al. · Epilepsy Research	18 Mar 2010	184
12	Pharmacokinetics and drug interactions of eslicarbazepine acetate Meir Bialer, Patrı́cio Soares-da-Silva · Epilepsia	21 May 2012	171
13	Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase László E. Kiss, Humberto S. Ferreira, Leonel Reis da Silva Torrao et al. · Journal of Medicinal Chemistry	24 Mar 2010	168
14	Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures António Gil‐Nagel, J. Lopes-Lima, Luís Guilherme Batista Almeida et al. · Acta Neurologica Scandinavica	9 Oct 2009	164
15	Molecular Characterization of American Cockroach Tropomyosin ( Periplaneta americana Allergen 7), a Cross-Reactive Allergen Juan Andrés Asturias, Nuria Gómez-Bayón, Maite Arilla et al. · The Journal of Immunology Open access	Apr 1999	148
16	Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide Simon Hebeisen, Nuno Marques Pires, Ana I. Loureiro et al. · Neuropharmacology	19 Sep 2014	139
17	Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features Hugo C. Ribeiro, Inês Patrício Rodrigues, Leonardo Napoleão et al. · Biomedicine & Pharmacotherapy Open access	19 Apr 2022	133
18	Eslicarbazepine Acetate: A Double‐blind, Add‐on, Placebo‐controlled Exploratory Trial in Adult Patients with Partial‐onset Seizures Christian Erich Elger, Meir Bialer, Joyce A. Cramer et al. · Epilepsia Open access	23 Feb 2007	133
19	Decrease of adenosine A 1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats Nelson Rebola, Joana Esteves Coelho, Ana Rita Costenla et al. · European Journal of Neuroscience	Aug 2003	123
20	Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial‐onset seizures: Results of a phase III , double‐blind, randomized, placebo‐controlled trial Michael R. Sperling, Bassel W Abou-Khalil, Jay H. Harvey et al. · Epilepsia Open access	22 Dec 2014	114
21	Pharmacokinetics of Trans‐resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects Teresa G. Nunes, Luís Guilherme Batista Almeida, José‐Francisco Rocha et al. · The Journal of Clinical Pharmacology	2 Oct 2009	110
22	Development of a Hypoallergenic Recombinant Parvalbumin for First-in-Man Subcutaneous Immunotherapy of Fish Allergy Laurian Zuidmeer et al. · International Archives of Allergy and Immunology Open access	2015	108
23	Single‐Dose and Steady‐State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2–093) in Healthy Elderly and Young Subjects Luís Guilherme Batista Almeida, Amílcar C. Falcão, Joana Maia et al. · The Journal of Clinical Pharmacology Open access	12 Aug 2005	103
24	Effect of food on the pharmacokinetic profile of trans-resveratrol Manuel Vaz‐da‐Silva, Ana I. Loureiro, Amílcar C. Falcão et al. · International Journal of Clinical Pharmacology and Therapeutics	Nov 2008	102
25	Medicinal Chemistry of CatecholO-Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility László E. Kiss, Patrı́cio Soares-da-Silva · Journal of Medicinal Chemistry	31 Jul 2014	101
26	Long‐term efficacy and safety of eslicarbazepine acetate: Results of a 1‐year open‐label extension study in partial‐onset seizures in adults with epilepsy Péter Halász, Joyce A. Cramer, Danilo Hodoba et al. · Epilepsia Open access	16 Jul 2010	100
27	Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment Luís Guilherme Batista Almeida, Johané Potgieter, Joana Maia et al. · European Journal of Clinical Pharmacology	20 Dec 2007	97
28	Long‐term Effect of Convulsive Behavior on the Density of Adenosine A1 and A2A Receptors in the Rat Cerebral Cortex Nelson Rebola, Lisiane O. Porciúncula, Luísa Vaqueiro Lopes et al. · Epilepsia Open access	29 Jun 2005	96
29	Interaction of the Novel Anticonvulsant, BIA 2‐093, with Voltage‐Gated Sodium Channels: Comparison with Carbamazepine Maria João Bonifácio, R.D. Sheridan, António Parada et al. · Epilepsia Open access	12 May 2001	96
30	Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists António Francisco Ambrósio, Ana Paula Silva, João Oliveira Malva et al. · Neuropharmacology Open access	Sep 1999	96
31	Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(−)-10,11-dihydro-10-hydroxy carbamazepine Dominik Hainzl, António Parada, Patrı́cio Soares-da-Silva · Epilepsy Research	May 2001	92
32	Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug Anna Doeser, G. Dickhof, Margit Reitze et al. · Brain	2 Dec 2014	89
33	Kinetics and Crystal Structure of Catechol-O-Methyltransferase Complex with Co-Substrate and a Novel Inhibitor with Potential Therapeutic Application Maria João Bonifácio, Margarida Archer, Maria Luı́sa Rodrigues et al. · Molecular Pharmacology	Oct 2002	88
34	Why healthy subjects volunteer for phase I studies and how they perceive their participation? Luís Guilherme Batista Almeida, Benedita Azevedo, Teresa G. Nunes et al. · European Journal of Clinical Pharmacology	19 Sep 2007	87
35	Opicapone: a short lived and very long acting novel catechol‐ O ‐methyltransferase inhibitor following multiple dose administration in healthy subjects Jose Francisco Xavier da Rocha, Luís Guilherme Batista Almeida, Amílcar C. Falcão et al. · British Journal of Clinical Pharmacology Open access	21 Jan 2013	87
36	Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects Luís Guilherme Batista Almeida, Jose Francisco Xavier da Rocha, Amílcar C. Falcão et al. · Clinical Pharmacokinetics	17 Dec 2012	87
37	Efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Integrated analysis of pooled data from double‐blind phase III clinical studies António Gil‐Nagel, Christian Erich Elger, Elinor Ben‐Menachem et al. · Epilepsia Open access	6 Aug 2012	86
38	Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double‐blind, randomized, parallel‐group, multicenter study Eugen Trinka, Elinor Ben‐Menachem, Pedro André Kowacs et al. · Epilepsia Open access	25 Jan 2018	85
39	Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets Anton Bespalov, Thomas Steckler, Bruce M. Altevogt et al. · Nature Reviews Drug Discovery Open access	17 Jun 2016	85
40	Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate Joana Maia, Luís Guilherme Batista Almeida, Amílcar C. Falcão et al. · International Journal of Clinical Pharmacology and Therapeutics	Mar 2008	83
41	Glucoamylase: another fungal enzyme associated with baker's asthma Santiago Quirce, Mar Fernández‐Nieto, Borja Bartolomé et al. · Annals of Allergy Asthma & Immunology	Aug 2002	80
42	Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study A. Hufnagel, Elinor Ben‐Menachem, Alberto Alain Gabbai et al. · Epilepsy Research	4 Aug 2012	80
43	Diagnosis of Alternaria alternata sensitization with natural and recombinant Alt a 1 allergens Juan Andrés Asturias, Ignacio Ibarrola, Angel Ferrer et al. · Journal of Allergy and Clinical Immunology Open access	15 Apr 2005	78
44	Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action Patrı́cio Soares-da-Silva, Nuno Marques Pires, Maria João Bonifácio et al. · Pharmacology Research & Perspectives Open access	Mar 2015	78
45	Purification and characterization of Pla a 1, a major allergen from Platanus acerifolia pollen Juan Andrés Asturias, Ignacio Ibarrola, Borja Bartolomé et al. · Allergy	Mar 2002	77
46	Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers Teresa G. Nunes, Jose Francisco Xavier da Rocha, Amílcar C. Falcão et al. · Epilepsia	19 Jul 2012	75
47	Is tropomyosin an allergen in Anisakis? Juan Andrés Asturias, Elena Eraso, Ignacio Moneo et al. · Allergy Open access	Sep 2000	73
48	Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase Maria Augusta Vieira‐Coelho, Patrı́cio Soares-da-Silva · Brain Research	Mar 1999	70
49	Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma Ana C. Fortuna, Joana Sousa, Gilberto Alves et al. · Analytical and Bioanalytical Chemistry	17 Apr 2010	70
50	Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen‐specific immunotherapy Juan Andrés Asturias, Ignacio Ibarrola, Maite Arilla et al. · Clinical & Experimental Allergy	21 Apr 2009	69

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.